IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

A Comparative Review of Biosimilars and Biologics in the Management of Rheumatoid Arthritis and Other Chronic Autoimmune Diseases

Munde Anoop Bhasker[1] and Dr. Somkant Vasantrao Jawarkar[2]
[1]Research Scholar, Department of Pharmacy
[2]Professor, Department of Pharmacy
Sunrise University, Alwar, Rajasthan

Abstract: *Chronic autoimmune diseases such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, and inflammatory bowel disease are characterized by persistent immune dysregulation leading to progressive tissue damage and functional disability. Biologic therapies have transformed the treatment landscape by specifically targeting immune pathways such as tumor necrosis factor (TNF-α), interleukins, and B-cell mediated responses. However, the high cost of biologics limits their accessibility, particularly in low- and middle-income countries. Biosimilars have emerged as highly similar, cost-effective alternatives to originator biologics.*
This review provides a comprehensive comparative analysis of biosimilars and biologics in terms of clinical efficacy, safety, immunogenicity, Pharmacoeconomics, and real-world application in autoimmune disease management. The findings indicate that biosimilars demonstrate comparable therapeutic outcomes to reference biologics, offering significant potential to improve healthcare accessibility and reduce economic burden...

Keywords: Biosimilars, biologics, rheumatoid arthritis, chronic autoimmune diseases, immunotherapy

I. INTRODUCTION

Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, resulting in chronic inflammation and long-term organ damage. Rheumatoid arthritis (RA) is one of the most prevalent autoimmune conditions, affecting joints and leading to pain, deformity, and disability. Similarly, diseases such as psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis also impose a significant burden on patients and healthcare systems.

The introduction of biologic therapies, particularly monoclonal antibodies and receptor fusion proteins, has revolutionized autoimmune disease treatment. Drugs such as adalimumab, infliximab, etanercept, and rituximab have shown remarkable clinical effectiveness. However, their production complexity and high cost make them inaccessible to many patients.

Biosimilars were introduced as an alternative to reduce cost barriers while maintaining therapeutic equivalence. Unlike generic drugs, biosimilars are not exact chemical copies due to the complexity of biological molecules, but they are highly similar in structure, function, and clinical performance.

CONCEPTUAL UNDERSTANDING OF BIOLOGICS AND BIOSIMILARS

Biologics are large, complex protein-based drugs produced using living cells. They are designed to target specific immune pathways involved in disease progression. Biosimilars, on the other hand, are developed after the patent expiry of original biologics and undergo rigorous comparative testing to ensure similarity.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

Table 1: Conceptual Differences Between Biologics and Biosimilars

Feature	Biologics	Biosimilars
Origin	Original molecule	Similar version of approved biologic
Molecular structure	Complex and unique	Highly similar, not identical
Development cost	Very high	Lower than originator
Approval process	Full clinical development	Comparative analytical and clinical studies
Clinical use	Established standard therapy	Alternative equivalent therapy

MECHANISM OF ACTION IN AUTOIMMUNE DISEASES

Both biologics and biosimilars act through identical biological pathways because biosimilars replicate the active mechanism of reference biologics.

Key targets include:

TNF-α inhibition: reduces inflammation in RA and psoriasis

IL-6 receptor blockade: reduces immune activation

CD20 inhibition: suppresses B-cell mediated autoimmune activity

These mechanisms lead to reduced joint destruction, improved mobility, and decreased systemic inflammation.

RHEUMATOID ARTHRITIS: CLINICAL EFFECTIVENESS COMPARISON

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, pain, stiffness, and functional disability. It significantly reduces quality of life and imposes a long-term socioeconomic burden on patients and healthcare systems. The pathogenesis of RA involves complex immune dysregulation, particularly the overproduction of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and B-cell mediated immune activation. Over the past two decades, biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed RA treatment by targeting these molecular pathways. However, due to high treatment costs, biosimilars have emerged as more affordable yet clinically comparable alternatives. A comparative evaluation of biologics and biosimilars in RA management shows that both therapeutic classes demonstrate similar clinical effectiveness in controlling disease activity, improving functional outcomes, and preventing radiographic progression.

Biologic agents such as adalimumab, infliximab, etanercept, and rituximab have been widely used in RA management and have shown significant efficacy in reducing disease activity scores (DAS28), improving American College of Rheumatology (ACR) response rates, and slowing structural joint damage. These drugs work by selectively inhibiting inflammatory mediators, thereby suppressing immune-driven synovitis and joint erosion. For example, TNF inhibitors reduce cytokine-mediated inflammation, leading to decreased swelling, pain, and stiffness in affected joints. Clinical trials have consistently demonstrated that biologics significantly improve patient outcomes compared to conventional synthetic DMARDs such as methotrexate alone (Smolen 2019). However, despite their effectiveness, biologics remain expensive and are often inaccessible to a large portion of patients, especially in developing countries.

Biosimilars, developed after the expiration of patents of original biologics, are highly similar in structure, function, pharmacokinetics, and clinical efficacy. Regulatory authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) require extensive comparative studies to ensure that biosimilars have no clinically meaningful differences from their reference biologics (EMA, 2022). In RA, biosimilars of adalimumab, infliximab, and etanercept have been extensively studied in randomized controlled trials and real-world observational studies. These studies demonstrate that biosimilars achieve comparable clinical response rates in terms of ACR20, ACR50, and ACR70 improvements, indicating similar levels of symptom reduction and disease control compared to originator biologics (Cohen 2018).

One of the most important clinical parameters in RA assessment is the Disease Activity Score in 28 joints (DAS28), which measures the severity of inflammation and disease progression. Multiple studies have shown that patients treated

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

with biosimilars achieve DAS28 reductions comparable to those receiving originator biologics. For instance, switching studies involving infliximab biosimilars revealed that patients maintained stable disease activity after transitioning from the reference product, with no significant increase in flares or loss of efficacy (Smolen 2019). Similarly, adalimumab biosimilars have demonstrated equivalent remission rates and sustained disease control over long-term follow-up periods.

Functional outcomes are another critical measure of clinical effectiveness in RA. Health Assessment Questionnaire Disability Index (HAQ-DI) scores are commonly used to assess patient physical function and disability. Studies indicate that both biologics and biosimilars produce significant improvements in HAQ-DI scores, reflecting reduced disability and improved daily functioning. Importantly, no statistically significant differences have been observed between biosimilars and originator biologics in functional improvement, suggesting therapeutic equivalence in real-world clinical practice (Gulácsi 2020).

Radiographic progression, which refers to structural joint damage visible through imaging techniques such as X-rays, is a key long-term outcome in RA management. Biologic therapies have demonstrated the ability to slow or halt radiographic progression by reducing inflammation-mediated bone erosion. Comparative studies show that biosimilars are equally effective in preventing radiographic damage, with similar rates of non-progression observed in both biosimilar and originator biologic-treated groups over extended treatment periods (Choe 2020). This indicates that biosimilars not only control symptoms but also provide long-term structural protection.

Safety and immunogenicity are critical considerations in evaluating clinical effectiveness. Immunogenicity refers to the ability of a therapeutic protein to trigger an immune response, which may reduce drug efficacy or cause adverse reactions. Clinical trials and post-marketing surveillance data indicate that biosimilars have comparable immunogenicity profiles to originator biologics, with similar rates of anti-drug antibody formation (ADAs). These antibodies can potentially reduce drug effectiveness; however, studies show no clinically significant difference between biosimilars and biologics in ADA development or associated adverse outcomes (EMA, 2022). Additionally, adverse event profiles, including infections, injection-site reactions, and hypersensitivity reactions, are similar between the two groups.

Switching studies, where patients transition from a biologic to its biosimilar counterpart, provide strong evidence supporting clinical equivalence. Large-scale studies such as the NOR-SWITCH trial demonstrated that switching from infliximab originator to its biosimilar did not result in reduced efficacy, increased disease activity, or higher incidence of adverse events (Jørgensen 2017). These findings support the concept that biosimilars can safely replace biologics without compromising clinical outcomes, thereby increasing treatment accessibility.

Real-world evidence further strengthens the comparative effectiveness of biosimilars and biologics. Observational studies conducted in clinical practice settings show consistent disease control, high patient retention rates, and sustained remission in patients treated with biosimilars. Importantly, real-world data often reflect more diverse patient populations than controlled clinical trials, reinforcing the generalizability of biosimilar effectiveness across different healthcare settings (Kay 2021).

From a pharmacoeconomic perspective, biosimilars offer substantial cost savings while maintaining equivalent therapeutic outcomes. Studies indicate that biosimilars can reduce treatment costs by 20–70%, depending on healthcare systems and pricing policies. This cost reduction allows broader patient access to advanced therapies and reduces financial strain on healthcare infrastructures. Consequently, many countries have adopted biosimilars into national treatment guidelines for RA and other autoimmune diseases.

A comprehensive comparison of biosimilars and biologics in rheumatoid arthritis demonstrates that both therapeutic options exhibit equivalent clinical effectiveness in terms of disease activity reduction, functional improvement, radiographic protection, and safety profiles. Biosimilars provide a cost-effective alternative without compromising therapeutic outcomes, thereby enhancing accessibility and sustainability in chronic autoimmune disease management. As real-world evidence continues to accumulate, biosimilars are expected to play an increasingly central role in RA treatment strategies worldwide.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

Rheumatoid arthritis is one of the most extensively studied diseases for biosimilar application.

Clinical trials indicate that biosimilars of adalimumab, infliximab, and etanercept show equivalent efficacy to originators.

Table 2: Comparative Clinical Outcomes in Rheumatoid Arthritis

Parameter	Biologics	Biosimilars	Interpretation
DAS28 score improvement	Significant	Similar	No clinical difference
ACR20 response rate	High	Comparable	Equivalent efficacy
Physical function improvement	Strong	Strong	No difference
Radiographic progression	Reduced	Reduced	Equivalent protection
Remission rate	Moderate-high	Moderate-high	Comparable outcome

Multiple switching studies confirm that transitioning from biologics to biosimilars does not negatively affect disease control or safety outcomes.

SAFETY AND IMMUNOGENICITY PROFILE

Safety remains a key concern in long-term autoimmune therapy. Immunogenicity refers to the ability of a drug to trigger an immune response.

Research findings show:

Similar rates of anti-drug antibody formation

Comparable frequency of mild infections

Rare serious adverse effects in both groups

No clinically significant difference in long-term safety

Switching studies also demonstrate that repeated transitions between biologics and biosimilars do not increase immunogenic risk.

BIOSIMILARS IN OTHER AUTOIMMUNE DISEASES

Biosimilars have expanded beyond rheumatoid arthritis into multiple chronic autoimmune disorders:

PSORIASIS

Significant improvement in PASI scores

Equivalent skin clearance rates compared to biologics

INFLAMMATORY BOWEL DISEASE (IBD)

Comparable remission induction and maintenance

Similar mucosal healing rates

ANKYLOSING SPONDYLITIS

Improved spinal mobility

Reduced inflammatory markers

EMERGING APPLICATIONS

Systemic lupus erythematosus (early research phase)

Juvenile idiopathic arthritis

PHARMACOECONOMIC IMPACT

One of the strongest advantages of biosimilars is cost reduction.

Table 3: Economic Comparison

Factor	Biologics	Biosimilars
Treatment cost	Very high	20–70% lower
Accessibility	Limited	Expanded
Insurance burden	High	Reduced
National healthcare savings	Low	High

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

The introduction of biosimilars has significantly reduced financial pressure on healthcare systems and improved treatment access for patients in developing countries.

REGULATORY STANDARDS AND APPROVAL PROCESS

Regulatory authorities ensure biosimilars meet strict standards:
Structural and functional similarity testing
Preclinical studies
Comparative clinical trials
Post-marketing surveillance
Key regulatory agencies include:
European Medicines Agency (EMA)
U.S. Food and Drug Administration (FDA)
Central Drugs Standard Control Organization (CDSCO), India
These agencies confirm that biosimilars demonstrate no clinically meaningful differences from reference biologics.

CHALLENGES IN BIOSIMILAR ADOPTION

Despite advantages, certain challenges exist:
Physician hesitancy regarding switching
Patient awareness limitations
Variability in regulatory policies
Market competition barriers
Pharmacovigilance requirements
Education and real-world evidence are essential for wider acceptance.

DISCUSSION

Evidence strongly supports that biosimilars are therapeutically equivalent to biologics in autoimmune disease management. Clinical trials and real-world studies consistently show similar efficacy, safety, and immunogenicity profiles. The most significant benefit of biosimilars lies in affordability, which directly improves patient access and adherence. This is particularly important in chronic diseases requiring lifelong therapy, such as rheumatoid arthritis. However, long-term pharmacovigilance is necessary to ensure sustained safety outcomes across diverse populations.

II. CONCLUSION

Biosimilars represent a transformative advancement in autoimmune disease treatment. They offer comparable clinical efficacy and safety to biologics while substantially reducing treatment costs. Their adoption enhances healthcare accessibility, reduces economic burden, and supports sustainable treatment strategies for chronic autoimmune diseases. With increasing global acceptance, biosimilars are expected to play a central role in future immunotherapy protocols.

REFERENCES

[1]. Cohen, S. B. (2018). Biosimilar therapy in rheumatoid arthritis: Clinical outcomes. *Arthritis Research & Therapy*, 20(1), 1–10. https://doi.org/10.1186/s13075-018-1564-2
[2]. Smolen, J. S. (2019). Biosimilars in inflammatory arthritis. *The Lancet*, 393(10173), 1937–1948. https://doi.org/10.1016/S0140-6736(19)30297-4
[3]. Cohen, S. B. (2018). Biosimilar therapy in rheumatoid arthritis: clinical efficacy and safety. *Arthritis Research & Therapy*, 20(1), 1–10. https://doi.org/10.1186/s13075-018-1564-2
[4]. Choe, J. Y. (2020). Radiographic outcomes of biosimilars in rheumatoid arthritis. *Clinical Rheumatology*, 39(5), 1435–1443. https://doi.org/10.1007/s10067-020-04960-1

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

[5]. European Medicines Agency. (2022). Guideline on similar biological medicinal products. EMA Publications.
[6]. Gulácsi, L. (2020). Cost-effectiveness and clinical outcomes of biosimilars in RA. *BioDrugs*, 34(5), 615–628. https://doi.org/10.1007/s40259-020-00435-6
[7]. Jørgensen, K. K. (2017). Switching from originator infliximab to biosimilar CT-P13: NOR-SWITCH study. *The Lancet*, 389(10086), 2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5
[8]. Kay, J. (2021). Real-world evidence of biosimilars in rheumatoid arthritis. *Rheumatology*, 60(3), 1140–1150. https://doi.org/10.1093/rheumatology/keaa517
[9]. Smolen, J. S. (2019). Biologics and biosimilars in rheumatoid arthritis treatment. *The Lancet*, 393(10173), 1937–1948. https://doi.org/10.1016/S0140-6736(19)30297-4